西妥昔单抗联合IMRT同步化疗治疗晚期鼻咽癌的疗效观察  

Curative effects of cetuximab combined with intensity modulated radiation therapy and concurrent chemotherapy on advanced nasopharyngeal carcinoma

作　　者：赵忠全[1] 欧阳学农[1] 余宗阳[1] 李捷[1] 王晗[1] 阴丽慧 

机构地区：[1]南京军区福州总医院肿瘤科,福州350025

出　　处：《西南国防医药》2015年第7期750-753,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的 观察西妥昔单抗联合调强适形放疗（IMRT）同步顺铂化疗治疗晚期鼻咽癌的临床疗效及不良反应。方法 选取2010年1月~2013年1月我科收治的64例晚期鼻咽癌患者随机分为实验组和对照组,每组32例。实试组给予西妥昔单抗联合适形放疗同步顺铂化疗,对照组给予适形放疗同步顺铂化疗,观察比较两组的临床疗效及不良反应。结果 治疗后近期疗效,室验组和对照组的总有效率分别为90.6%和68.8%,疾病控制率分别为100.0%和81.3%;远期疗效,实验组和对照组的总有效率分别为78.1%和53.1%,疾病控制率分别为96.9%和75.0%。实验组的近、远期疗效均优于对照组（P〈0.05）,两组不良反应发生情况未见明显差异（P〉0.05）。结论 西妥昔单抗联合适形放疗同步顺铂化疗治疗晚期鼻咽癌具有较好的临床疗效和安全性,值得临床推广。Objective To observe the clinical curative effects of cetuximab combined with intensity modulated radiation therapy （IMRT） and concurrent cisplatin chemotherapy on advanced nasopharyngeal carcinoma and the adverse reactions. Methods Sixty four cases of advanced nasopharyngeal carcinoma hospitalized between January 2010 and January 2013 were randomly divided into experimental group and control group with 32 ones in each group. The experimental group received cetuximab combined with IMRT and concurrent cisplatin chemotherapy, while the control group received conformal therapy and concurrent cisplatin chemotherapy. Observation and comparison were made in the clinical curative effects and adverse reactions between the two groups. Results After the therapy, the total effective rates of short term clinical curative effect in the experimental and the control groups were 90.6% and 68.8%, respectively; the treatment control rates were 100.0% and 81.3% ,respectively. The total effective rates of long term clinical curative effect in the experimental and the control group were 78.1% and 53.1%, respectively; the treatment control rotes were 96.9% and 75.0%, respectively. The short and long term clinical curative effects in the experimental group were all superior to those in the control greup（P 〈 0.05）. However, there was no significant difference in the occurrence of adverse reactions between the two groups （P 〉 0.05）. Conclusion Cetuximab combined with IMRT and concurrent cisplatin chemotherapy have a superior clinical curative effect and safety on advanced nasopharyngeal carcinoma, which is worthwhile to be promoted.

关 键 词：西妥昔单抗 调强适形放疗 鼻咽癌 同步 化疗 

分 类 号：R739.6[医药卫生—肿瘤]